Abionyx Pharma SA (ABNX) - Total Liabilities

Latest as of June 2025: €7.56 Million EUR ≈ $8.84 Million USD

Based on the latest financial reports, Abionyx Pharma SA (ABNX) has total liabilities worth €7.56 Million EUR (≈ $8.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Abionyx Pharma SA cash flow conversion to assess how effectively this company generates cash.

Abionyx Pharma SA - Total Liabilities Trend (2013–2024)

This chart illustrates how Abionyx Pharma SA's total liabilities have evolved over time, based on quarterly financial data. Check Abionyx Pharma SA (ABNX) asset resilience to evaluate the company's liquid asset resilience ratio.

Abionyx Pharma SA Competitors by Total Liabilities

The table below lists competitors of Abionyx Pharma SA ranked by their total liabilities.

Company	Country	Total Liabilities
Bank Qnb Indonesia Tbk JK:BKSW	Indonesia	Rp7.02 Trillion
Moens Bank A/S CO:MNBA	Denmark	Dkr4.61 Billion
Garuda Metalindo Tbk PT JK:BOLT	Indonesia	Rp581.39 Billion
Silk Logistics Holdings Ltd AU:SLH	Australia	AU$479.39 Million
Joyce Corporation Ltd AU:JYC	Australia	AU$57.55 Million
Arena Group Holdings Inc NYSE MKT:AREN	USA	$131.75 Million
Gabelli Global Small and Mid Cap Value Closed Fund NYSE:GGZ	USA	$16.29 Million
G50 Corp Ltd AU:G50	Australia	AU$2.40 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Abionyx Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABNX company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.40	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Abionyx Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Abionyx Pharma SA (2013–2024)

The table below shows the annual total liabilities of Abionyx Pharma SA from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	€6.03 Million ≈ $7.05 Million	-12.82%
2023-12-31	€6.91 Million ≈ $8.08 Million	-20.13%
2022-12-31	€8.65 Million ≈ $10.12 Million	-22.42%
2021-12-31	€11.15 Million ≈ $13.04 Million	+204.86%
2020-12-31	€3.66 Million ≈ $4.28 Million	+2.12%
2019-12-31	€3.58 Million ≈ $4.19 Million	-61.46%
2018-12-31	€9.30 Million ≈ $10.87 Million	-1.18%
2017-12-31	€9.41 Million ≈ $11.00 Million	-34.91%
2016-12-31	€14.46 Million ≈ $16.90 Million	+11.98%
2015-12-31	€12.91 Million ≈ $15.09 Million	+19.24%
2014-12-31	€10.82 Million ≈ $12.66 Million	+39.44%
2013-12-31	€7.76 Million ≈ $9.08 Million	--

About Abionyx Pharma SA

PA:ABNX France Biotechnology

Market Cap

$142.30 Million

€121.71 Million EUR

Market Cap Rank

#18388 Global

#277 in France

Share Price

€3.45

Change (1 day)

-1.43%

52-Week Range

€1.20 - €5.00

All Time High

€12.79